In countries where PSA screening is not widely adopted, the incidence of diagnosis of metastatic prostate cancer is significantly higher than in other countries, and the metastatic prostate cancer eventual emergence of castration resistance results in the lethal phenotype termed metastatic castration-resistant prostate cancer (mCRPC). This evidence concerns the gene KLK3 and metastatic prostate carcinoma.